Deprenyl — Past and Future
Latest Publications

TOTAL DOCUMENTS

(FIVE YEARS 0)

H-INDEX

(FIVE YEARS 0)

Published By Springer Vienna

9783211828915, 9783709174944

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

New aspects of pathology in Parkinson’s disease with concomitant incipient Alzheimer’s disease

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_1 ◽

1996 ◽

pp. 1-6 ◽

Cited By ~ 2

Author(s):

H. Braak ◽

E. Braak ◽

D. Yilmazer ◽

R. A. I. Vos ◽

E. N. H. Jansen ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Parkinson’S Disease ◽

Alzheimer's Disease ◽

Parkinson's Disease

Download Full-text

New horizons in molecular mechanisms underlying Parkinson’s disease and in our understanding of the neuroprotective effects of selegiline

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_2 ◽

1996 ◽

pp. 7-21

Author(s):

M. Gerlach ◽

H. Desser ◽

M. B. H. Youdim ◽

P. Riederer

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Molecular Mechanisms ◽

Neuroprotective Effects ◽

New Horizons

Download Full-text

The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (−)-deprenyl research

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_4 ◽

1996 ◽

pp. 29-43

Author(s):

K. Magyar ◽

B. Szende ◽

J. Lengyel ◽

K. Tekes

Keyword(s):

Monoamine Oxidase ◽

Monoamine Oxidase Inhibitors

Download Full-text

The clinical potential of Deprenyl in neurologic and psychiatric disorders

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_8 ◽

1996 ◽

pp. 85-93

Author(s):

W. Kuhn ◽

Th. Müller

Keyword(s):

Psychiatric Disorders ◽

Clinical Potential

Download Full-text

Early diagnosis in Parkinson’s disease — limitation of biochemical markers and instrumental methods

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_3 ◽

1996 ◽

pp. 23-28

Author(s):

P. H. Kraus

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Early Diagnosis ◽

Biochemical Markers ◽

Instrumental Methods

Download Full-text

Pharmacology and neuroprotective properties of rasagiline

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_9 ◽

1996 ◽

pp. 95-101 ◽

Cited By ~ 5

Author(s):

J. P. M. Finberg ◽

I. Lamensdorf ◽

J. W. Commissiong ◽

M. B. H. Youdim

Download Full-text

Potential of neurotrophic factors in therapy of Parkinson’s disease

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_10 ◽

1996 ◽

pp. 103-112

Author(s):

J. C. Möller ◽

J. Sautter ◽

A. Kupsch

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Neurotrophic Factors

Download Full-text

Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_6 ◽

1996 ◽

pp. 61-73 ◽

Cited By ~ 1

Author(s):

S. Yasar ◽

J. P. Goldberg ◽

S. R. Goldberg

Keyword(s):

Preclinical Research

Download Full-text

(−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_5 ◽

1996 ◽

pp. 45-59 ◽

Cited By ~ 2

Author(s):

W. G. Tatton ◽

J. S. Wadia ◽

W. Y. H. Ju ◽

R. M. E. Chalmers-Redman ◽

N. A. Tatton

Keyword(s):

Protein Synthesis ◽

Monoamine Oxidase ◽

Neuronal Apoptosis ◽

Neuronal Outgrowth

Download Full-text

Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism of action

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_7 ◽

1996 ◽

pp. 75-84

Author(s):

C. W. Olanow

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mechanism Of Action ◽

Clinical Effects

Download Full-text

Deprenyl — Past and FutureLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By Springer Vienna

New aspects of pathology in Parkinson’s disease with concomitant incipient Alzheimer’s disease

New horizons in molecular mechanisms underlying Parkinson’s disease and in our understanding of the neuroprotective effects of selegiline

The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (−)-deprenyl research

The clinical potential of Deprenyl in neurologic and psychiatric disorders

Early diagnosis in Parkinson’s disease — limitation of biochemical markers and instrumental methods

Pharmacology and neuroprotective properties of rasagiline

Potential of neurotrophic factors in therapy of Parkinson’s disease

Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research

(−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase

Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism of action

Deprenyl — Past and Future
Latest Publications